



(12) Translation of
European patent specification

(11) NO/EP 3849534 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/5025 (2006.01)

A61K 31/519 (2006.01)

A61K 45/06 (2006.01)

A61K 9/00 (2006.01)

A61K 31/5377 (2006.01)

A61P 35/00 (2006.01)

A61K 31/506 (2006.01)

A61K 31/541 (2006.01)

A61P 35/02 (2006.01)

A61K 31/517 (2006.01)

A61K 31/553 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2025.05.05
(80)	Date of The European Patent Office Publication of the Granted Patent	2025.03.05
(86)	European Application Nr.	19858883.2
(86)	European Filing Date	2019.09.09
(87)	The European Application's Publication Date	2021.07.21
(30)	Priority	2018.09.10, US, 201862729169 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	Mirati Therapeutics, Inc., Route 206 and Province Line Road, Princeton, New Jersey 08543, USA
(72)	Inventor	ENGSTROM, Lars, Daniel, 7974 Amargosa Dr., Carlsbad, CA 92009, USA ARANDA, Ruth, Wei, 10797 San Diego Mission Rd. Unit 311, San Diego, CA 92108, USA OLSON, Peter, 4763 Robbins St., San Diego, CA 92122, USA CHRISTENSEN, James, Gail, 4276 Kenwood ct., San Diego, CA 92130, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54) Title **COMBINATION OF DASATINIB AND ADAGRASIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER**


(56) References

Cited:

US-A1- 2016 108 019, WO-A1-2018/140600, US-A1- 2018 072 723, US-A1- 2019 144 444, US-A1- 2016 166 571,
BRIERE DAVID M. ET AL: "The KRAS G12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy", MOLECULAR CANCER THERAPEUTICS, vol. 20, no. 6, 15 March 2021 (2021-03-15), US, pages 975 - 985, XP055891872, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-20-0462
RAO ET AL.: "Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity", EUROPEAN JOURNAL OF CANCER, vol. 99, 11 June 2018 (2018-06-11), pages 37 - 48, XP055693960
HALLIN JILL ET AL: "The KRAS G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients", CANCER DISCOVERY, vol. 10, no. 1, 1 January 2020 (2020-01-01), US, pages 54 - 71, XP055892065, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-19-1167
AWAD MARK M. ET AL: "Acquired Resistance to KRAS G12C Inhibition in Cancer", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 384, no. 25, 24 June 2021 (2021-06-24), US, pages 2382 - 2393, XP055920424, ISSN: 0028-4793, DOI: 10.1056/NEJMoa2105281

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

hvor kinaseinhibitoren av Src-familien er dasatinib,
hvori KRAS G12C-inhibitoren er:



2. Farmasøytisk sammensetning, omfattende en terapeutisk virksam mengde av en kombinasjon av en kinaseinhibitor av Src-familien og en KRAS G12C-inhibitor ifølge krav 1, og en farmasøytisk akseptabel eksipiens for anvendelse innen behandling av ikke-småcellet lungekreft.

20 **3.** Kombinasjonen av en kinaseinhibitor av Src-familien og en KRAS G12C-inhibitor for anvendelse ifølge krav 1, hvori den terapeutisk virksomme mengden av KRAS G12C-inhibitoren i kombinasjonen er mellom 0,01 og 100 mg/kg per dag.